Référentiel des médicaments
Trilaciclib
Trilaciclib is a medicine in the class oncology.
- Classe médicamenteuse: Oncology
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Oncology
- Formes courantes
- injection
- Dosages courants
- 300 mg/20 ml
- Interactions connues
- 28 (Majeure: 12 · Modérée: 13 · Mineure: 3)
- Noms commerciaux
- 1
- Pays et marchés
- 1
Mécanisme d'action
Transient inhibitor of CDK 4 and 6; proliferation of hematopoietic stem and progenitor cells in bone marrow depends on CDK4/6 activity.
Posologie adulte habituelle (résumé de la notice)
Decrease chemotherapy-induced myelosuppression in ES-SCLC: 240 mg/m2 as a 30-minute intravenous infusion completed no more than 4 hours before chemotherapy on each chemotherapy day; interval between doses on sequential days not greater than 28 hours
Grossesse et allaitement
- Grossesse
- Unsafe Can cause fetal harm based on its mechanism (CDK4/6 inhibitor); no human or animal data. Pregnancy test before starting; contraception during treatment and for at least 3 weeks after the last dose.
- Allaitement
- Unsafe No data on milk levels or infant effects. Because of possible serious infant reactions, do not breastfeed during treatment and for at least 3 weeks after the last dose.
Effets indésirables signalés
- Fatigue
- Hypocalcemia
- Hypokalemia
- Hypophosphatemia
- Increased aspartate aminotransferase
- Headache
Contre-indications
- History of serious hypersensitivity reactions to trilaciclib, including anaphylaxis.
Précautions particulières
- Injection-site reactions including phlebitis and thrombophlebitis; monitor, and stop infusion and permanently discontinue for severe or life-threatening reactions.
- Acute hypersensitivity reactions including facial edema, urticaria and anaphylaxis; withhold for moderate, permanently discontinue for severe or life-threatening.
- Interstitial lung disease/pneumonitis; monitor for cough, dyspnea, hypoxia and permanently discontinue for recurrent symptomatic or severe/life-threatening cases.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (28)
- Alogliptin-metformin + Trilaciclib Major
- Canagliflozin-metformin + Trilaciclib Major
- Cisplatin + Trilaciclib Major
- Dalfampridine + Trilaciclib Major
- Dapagliflozin-metformin + Trilaciclib Major
- Empagliflozin-metformin + Trilaciclib Major
- Glyburide-metformin + Trilaciclib Major
- Linagliptin-metformin + Trilaciclib Major
- Metformin + Trilaciclib Major
- Metformin-pioglitazone + Trilaciclib Major
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Trilaciclib : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
Essayez Pro+ gratuitement pendant 7 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Trilaciclib used for?
Trilaciclib is a medicine in the class oncology.
What side effects have been reported with Trilaciclib?
Fatigue, Hypocalcemia, Hypokalemia, Hypophosphatemia, Increased aspartate aminotransferase, Headache.
Can Trilaciclib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm based on its mechanism (CDK4/6 inhibitor); no human or animal data. Pregnancy test before starting; contraception during treatment and for at least 3 weeks after the last dose. Breastfeeding: Unsafe. No data on milk levels or infant effects. Because of possible serious infant reactions, do not breastfeed during treatment and for at least 3 weeks after the last dose.
What does Trilaciclib interact with?
MediHelp lists 28 known interactions for Trilaciclib. Major: 12 · Moderate: 13 · Minor: 3. The most serious include Alogliptin-metformin, Canagliflozin-metformin, Cisplatin.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
